Chimerix

Site Map


About Us

Therapeutic Programs

Scientific Foundation

News & Resources

Careers

Contact Us

Site Map

Terms of Use

Privacy Policy

Featured News & Events

Chimerix Announces Completion of Initial Public Offering and Exercise of Underwriters’ Over-allotment Option

Chimerix Announces Pricing of Initial Public Offering

Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting

Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer

FDA Grants Fast Track Designation for CMX001 for the Prevention of Clinically Significant CMV Infection